Aeovian Pharmaceuticals
Berkeley, US · Founded 2012 · Delaware corporation · 6 known investors
Find your way into Aeovian Pharmaceuticals
580 people in our graph share verified history with the Aeovian Pharmaceuticals team — schools, employers, funds. One of them is your warm intro.
Anthony Linunlockedknows Davis Ryman · together at University of California, Berkeley (overlapped)
×4knows the team · via University of California, Berkeley
×4knows the team · via Case Western Reserve University
knows the team · via AbbVie
knows the team · via Case Western Reserve University School of Medicine
knows the team · via Lawrence Berkeley National Laboratory
Aeovian Pharmaceuticals is a clinical-stage biopharmaceutical company developing selective small molecule inhibitors to treat rare genetic and age-related diseases caused by dysregulated cellular metabolism. The company's lead candidate, AV078, is a CNS-penetrant mTORC1 inhibitor in development for tuberous sclerosis complex refractory epilepsy.
Founders & leadership
AJ
Allison J. HulmeinCEO & President
JK
John KincaidinChief Scientific Officer
DR
Davis RymaninChief Medical OfficerBoard-certified neurologist and geneticist with over 10 years of experience in pharmaceutical and biotechnology development and academic research focused on neurological and genetic disorders. Ryman has led clinical development programs for multiple neurological indications including spinal muscular atrophy, Alzheimer's disease, and Parkinson's disease, with contributions to FDA-approved therapies including ZOLGENSMA and DUOPA.
MZ
Micah ZajicinChief Financial Officer
IM
Ian MasseyNamed on SEC filing
ST
Stelios TzannisNamed on SEC filing
BZ
Ben ZadikNamed on SEC filing
DL
David LoweNamed on SEC filing
JP
James PeyerNamed on SEC filing
Board
RG
YB
TK
Themasap KhanBoard director
Investors · 6
Reported raises · per SEC filings
Form D private placements$125M disclosed across 4 rounds · 2017–2025
▶$55MraisedDec 2025 · 13 investors · PharmaceuticalsRule 506(b)
▶$55MraisedDec 2025 · 13 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- John KincaidExecutive Officer
- Youssef BennaniDirector
- Themasap KhanDirector
- Nils ReggeDirector
- Davis RymanExecutive Officer
- William GreeneDirector
- Micah ZajicExecutive Officer
- Lars EkmanDirector
- Justin GoverDirector
- Allison J. HulmeExecutive Officer, Director
- Richard GasterDirector
- Offering amount
- $55M
- Amount sold
- $55M
- First sale
- Nov 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$50.4MraisedMay 2024 · 5 investors · PharmaceuticalsRule 506(b)
▶$50.4MraisedMay 2024 · 5 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Davis C. RymanExecutive Officer
- Nils ReggeDirector
- Matthew J. PlunkettExecutive Officer
- William GreeneDirector
- Allison J. HulmeExecutive Officer, Director
- John F. KincaidExecutive Officer
- Richard GasterDirector
- Lars EkmDirector
- Offering amount
- $50.4M
- Amount sold
- $50.4M
- First sale
- Dec 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$18.8MraisedOct 2019 · 5 investors · PharmaceuticalsRule 506(b)
▶$18.8MraisedOct 2019 · 5 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Stelios TzannisExecutive Officer, Director
- Jens EcksteinDirector
- Ben ZadikExecutive Officer
- Michael PowellDirector
- Richard GasterDirector
- Offering amount
- $48.8M
- Amount sold
- $18.8M
- First sale
- Sep 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$785.7KraisedJun 2017 · 4 investors · PharmaceuticalsRule 506(b)
▶$785.7KraisedJun 2017 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Ian MasseyExecutive Officer
- Stelios TzannisExecutive Officer, Director
- Ben ZadikExecutive Officer
- David LoweDirector
- James PeyerDirector
- Offering amount
- $3.8M
- Amount sold
- $785.7K
- First sale
- Jun 2017
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 5
by search overlap
Elevian16 shared keywordsElevian is a biotechnology company developing rGDF11, a recombinant protein therapy shown in preclinical animal models to promote recovery of motor function after ischemic and hemorrhagic stroke by stimulating new blood vessel formation, neurogenesis, and reducing inflammation. The protein has also shown regenerative effects in preclinical models of aging-related cardiovascular, neurological, metabolic, pulmonary, renal, and skeletal muscle conditions.
Actio Biosciences, Inc.14 shared keywordsActio is a precision medicine company that translates genetic insights into new therapeutics, developing drugs that target the genes underlying both rare diseases and more prevalent conditions. It focuses on identifying dysregulated gene activity and designing therapies to restore balance and address the root causes of disease.
IQVIA11 shared keywordsIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.
Azevan9 shared keywordsAzevan Pharmaceuticals is a clinical-stage biopharmaceutical company developing orally bioavailable V1a receptor antagonists targeting vasopressin biology for neuropsychiatric, neurodegenerative, neurodevelopmental, and brain injury conditions. The company's lead candidate SRX246 has shown efficacy in reducing pathological aggression in Huntington's Disease and Intermittent Explosive Disorder.
Attovia Therapeutics9 shared keywordsAttovia is a biotechnology company focused on drug development and clinical strategy, aiming to bring treatments to patients where none exist and create next-generation therapeutic options. Its team includes a leadership team, board of directors, and scientific advisors experienced in drug development and company building.
Companies competing with Aeovian Pharmaceuticals for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Aeovian Pharmaceuticals do?
- Aeovian Pharmaceuticals is a clinical-stage biopharmaceutical company developing selective small molecule inhibitors to treat rare genetic and age-related diseases caused by dysregulated cellular metabolism. The company's lead candidate, AV078, is a CNS-penetrant mTORC1 inhibitor in development for tuberous sclerosis complex refractory epilepsy.
- Who are Aeovian Pharmaceuticals's investors?
- Aeovian Pharmaceuticals's investors include CoastCap, CTI Life Sciences Fund L.P., FJ Labs, Sofinnova Ventures, venBio Partners, venBio Global Strategic.
- How much funding has Aeovian Pharmaceuticals raised?
- Aeovian Pharmaceuticals has disclosed $125M raised across 4 rounds.
- Where is Aeovian Pharmaceuticals headquartered?
- Aeovian Pharmaceuticals is headquartered in Berkeley, US.